scroll
LEARN MORE
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
ASX.CUV $17.77
20 MINUTE DELAYED
ANALYSIS
OPINION
ACTION
i
PERFORMANCE
i
SHARE PRICE ACTIVITY | |
---|---|
Last (Price) | 17.77 |
Change | 0.07 (0.40) |
Bid / Ask | 17.77 - 17.92 |
Volume | 68,739 |
Volume (3mths avg) | 0 |
Turnover | 1,228,523 |
Open | 17.71 |
Day Range | 17.59 - 18.19 |
VWAP | 17.87 |
Prev Close | 17.70 |
Last Trade | 01/12 4:10pm (AEST) |
i
KEY INFORMATION | |
---|---|
Sector | Healthcare |
Shares Issued | 36,855,238 |
NTA/Share | 0.00 |
Last Dividend | 0.05 |
Dividend Ex Date | 05 SEP 2023 |
Dividend Pay Date | 20 SEP 2023 |
i
CURRENT () | |
---|---|
Revenue | |
EBITDA | |
Profit | |
Earnings Per Share (EPS) | 0 |
Dividend Per Share (DPS) | 0 |
Yield % | 0.28 |
Market Cap | 0 |
Price to Earnings Ratio (P/E) | 28.71 |
i
TARGET PRICE FORECAST
i
ESTIMATES () | |
---|---|
Revenue | 0.00 |
EBITDA | 0.00 |
Profit | 0.00 |
Earnings Per Share (EPS) | 0.00 |
Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation ()
0.00
ACTION
CUV
UPDATED
22/03/2022 23:08
Business Summary
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. Its principal activity consists of commercializing and distribution in Europe and the United States, Israel, and Australia of its drug candidate SCENESSE for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural α-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.Relevant suggested news and content from the site
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here